Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
JAMA Surgery,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 19, 2025
Importance
The
association
of
neoadjuvant
chemoimmunotherapy
(NCIT)
vs
chemoradiotherapy
(NCRT)
with
tumor
downstaging
and
survival
in
locally
advanced
esophageal
squamous
cell
carcinoma
(ESCC)
remains
unclear
because
limited
evidence.
Objective
To
compare
the
associations
NCIT
NCRT
regression
long-term
patients
ESCC.
Design,
Setting,
Participants
In
this
comparative
effectiveness
research
study,
from
January
2016
to
March
2023,
ESCC
who
underwent
esophagectomy
following
or
were
identified
a
prospective
database
8
high-volume
surgery
centers
China.
Follow-up
began
on
date
continued
until
last
recorded
contact
2024,
whichever
occurred
first.
Data
analyzed
between
April
September
2024.
Main
Outcomes
Measures
primary
end
points
2-year
overall
(OS)
disease-free
(DFS).
Secondary
included
major
pathologic
response
(MPR)
complete
(pCR).
Cox
proportional
hazard
analysis
was
used
investigate
risk
factors
for
OS
DFS.
Results
study
1428
(median
[IQR]
age,
63
[57-68]
years;
1184
men
[82.9%]),
704
group
724
group.
After
propensity
score
matching,
there
532
each
(81.3%
71.3%;
ratio,
1.57;
95%
CI,
1.26-1.96;
P
<
.001)
DFS
(73.9%
63.4%;
1.37;
1.11-1.69;
rates
significantly
higher
than
had
MPR
rate
that
(71.8%
61.5%),
whereas
pCR
similar
(25.9%
22.9%).
Multivariable
demonstrated
independently
associated
both
exhibited
lower
recurrence
(126
[23.7%]
190
[35.7%])
distant
metastasis
(72
[13.5%]
133
[25.0%]),
although
locoregional
(98
[18.4%]
111
[20.9%]).
Better
obtained
group,
regardless
whether
adjuvant
immunotherapy
given.
Conclusions
Relevance
Compared
NCRT,
receiving
better
decrease
may
be
main
reason,
but
further
randomized
clinical
trials
are
needed
verify
finding.
Язык: Английский
Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 24, 2025
The
aim
of
this
study
was
to
investigate
the
survival
benefits
postoperative
radiotherapy
(PORT)
in
patients
with
resectable
esophageal
cancer
(EC)
after
neoadjuvant
therapy
Immunotherapy
era.
designed
as
a
retrospective
cohort
study,
which
included
total
733
EC
from
SEER
database
and
single-center
cohort.
We
used
propensity
score
matching
(PSM)
equilibrate
patient
characteristics.
investigation
incorporated
Kaplan-Meier
analysis
Cox
proportional
risk
regression
model
assess
outcomes.
PORT
did
not
significantly
improve
overall
cohort,
median
38
months
(p=0.56)
39
(p=0.75)
Chinese
However,
immunotherapy
subgroup,
demonstrated
that
combined
improved
(p=0.044).Multivariate
aged
50-59
years
(HR=5.93,
95%
CI:
1.67-21.06)
those
≥70
(HR=10.96,
CI:3.04-39.56)
had
increased
risks
compared
<50
years.
Additionally,
ypT3-4
stage
exhibited
higher
than
ypT1-2
(HR=2.12,
1.14-3.93,
p=0.017).Similar
trends
were
observed
cT3-4
staging,
R1/R2
no
immunotherapy.
Lymph
node
metastasis
also
showed
progressive
relationship
risk,
categorized
ypN1
(HR=1.90),
ypN2
(HR=4.24),
ypN3
(HR=6.68)
experiencing
increasingly
(p<0.05).
collaborative
effect
potentially
enhances
outcomes
for
EC.
further
prospective
research
is
essential
confirm
our
results.
Язык: Английский
Impact of Adjuvant Immunotherapy on Prognosis in Esophageal Squamous Cell Carcinoma Patients Following Neoadjuvant Immunochemotherapy
Jiayi Geng,
Bengang Hui,
Teng Mu
и другие.
Опубликована: Янв. 1, 2025
Язык: Английский
Regulatory mechanisms of m6A RNA methylation in esophageal cancer: a comprehensive review
Frontiers in Genetics,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 22, 2025
Esophageal
cancer
is
an
aggressively
malignant
neoplasm
characterized
by
a
high
mortality
rate.
Frequently
diagnosed
at
advanced
stage,
it
presents
challenges
for
optimal
therapeutic
intervention
due
to
its
non-specific
symptoms,
resulting
in
lost
opportunities
effective
treatment,
such
as
surgery,
radiotherapy,
chemotherapy
and
target
therapy.
The
N6-methyladenosine
(m6A)
modification
represents
the
most
critical
post-transcriptional
of
eukaryotic
messenger
RNA
(mRNA).
reversible
m6A
mediated
three
regulatory
factors:
methyltransferases,
demethylating
enzymes,
recognition
proteins.
These
components
identify
bind
specific
methylation
sites,
thereby
modulating
essential
biological
functions
processing,
nuclear
export,
stability,
translation
degradation,
which
significantly
influence
tumorigenesis,
invasion,
metastasis.
Given
importance
modification,
this
paper
offers
comprehensive
examination
mechanisms,
functions,
future
implications
context
esophageal
cancer.
Язык: Английский
Circulating Tumor DNA Dynamic Changes in Esophageal Squamous Cell Carcinoma Receiving Immunochemotherapy
Thoracic Cancer,
Год журнала:
2025,
Номер
16(9)
Опубликована: Май 1, 2025
ABSTRACT
Background
Immune
checkpoint
inhibitors
have
revolutionized
the
treatment
strategy
of
esophageal
squamous
cell
carcinoma
(ESCC).
The
value
ctDNA
dynamic
changes
in
ESCC
patients
treated
with
immunochemotherapy
was
not
clear.
Methods
A
retrospective
analysis
performed
to
analyze
association
efficacy
locally
advanced,
metastatic,
or
recurrent
and
who
received
at
Department
Medical
Oncology,
National
Cancer
Center
from
June
2023
December
2024.
Tumor
mutation
burden
(TMB)
PD‐L1
expression
tumor
tissue
were
also
explored.
Results
57
paired
baseline
during
analyzed.
We
found
that
negative
demonstrated
a
higher
regression
rate
(96.8%
vs.
73.1%;
p
=
0.018)
cCR
(45.2%
15.4%;
0.022).
Additionally,
continuously
(
0.033)
experienced
clearance
0.043)
had
compared
those
persistently
positive
ctDNA.
Moreover,
among
TP53
mutations
baseline,
cleared
showed
(88.9%
54.5%;
0.031)
(33.3%
0%;
0.038)
persistent
mutations.
No
correlation
observed
between
TMB
efficacy,
while
CPS
≥
15
(63.6%
24.4%;
0.027).
Conclusions
potential
predictive
for
ESCC.
Further
exploration
through
larger‐scale
studies
is
necessary.
Язык: Английский
Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
BMC Gastroenterology,
Год журнала:
2025,
Номер
25(1)
Опубликована: Май 29, 2025
Neoadjuvant
chemotherapy
(NC)
is
a
cornerstone
in
the
management
of
resectable
esophageal
squamous
cell
carcinoma
(ESCC).
The
integration
PD-1/PD-L1
inhibitors
into
NC
(NIC)
regimens
has
shown
promise;
however,
its
efficacy
and
safety
remain
uncertain.
This
meta-analysis
aims
to
compare
potential
risks
clinical
benefits
NIC
versus
patients
with
ESCC
based
on
randomized
controlled
trials
(RCTs).
A
thorough
search
six
databases
was
performed
identify
RCTs
evaluating
ESCC.
Key
outcomes
analyzed
included
pathological
complete
response
(pCR)
rate
major
(MPR)
rate.
Other
overall
survival
(OS),
event-free
(EFS),
surgery
rate,
R0
resection
adverse
events
(AEs).
Four
encompassing
605
were
included.
significantly
improved
pCR
(risk
ratio
[RR]:
2.66
[1.63,
4.34],
P
<
0.0001)
MPR
(RR:
1.74
[1.02,
2.95],
=
0.04)
compared
group.
Only
one
phase
III
RCT
reported
outcomes,
showing
that
group
demonstrated
OS
(HR:
0.48
[0.24,
0.96],
EFS
0.62
[0.39,
0.99],
0.05).
Additionally,
1.11
[1.03,
1.20],
0.008)
number
resected
lymph
nodes
(mean
difference
[MD]:
3.91
[0.60,
7.21],
0.02)
also
higher
duration
surgery,
intraoperative
blood
loss
comparable
between
groups.
However,
immune-related
AEs
(irAEs)
40.80
[5.67,
293.37],
0.0002)
Similar
surgical
complications
observed
two
demonstrates
superior
improving
alone,
may
potentially
provide
benefits,
although
it
associated
risk
irAEs.
Язык: Английский
Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Июнь 4, 2025
Esophageal
cancer
(EC),
especially
esophageal
squamous
cell
carcinoma
(ESCC),
which
is
the
most
common
subtype
in
China,
one
of
aggressive
gastrointestinal
malignancies.
Traditional
treatments
like
surgery,
radiotherapy,
and
chemotherapy
have
limited
success,
but
study
tertiary
lymphoid
structure
(TLS)
has
opened
new
avenues
for
immunotherapy.
TLS
an
ectopic
immune
cluster,
including
B
cells,
T
dendritic
cells
(DCs),
that
forms
chronic
inflammation
such
as
tumors.
often
found
at
tumor
invasion
margins
linked
to
better
prognosis
EC
patients,
with
higher
density
maturation
associated
prolonged
survival.
can
also
serve
a
biomarker
assess
immunotherapy
outcomes.
Further
exploration
molecular
mechanisms
could
innovate
treatments,
by
inducing
formation
improve
therapy.
This
review
summarizes
characteristics
EC,
clinical
findings,
limitations
directions
current
research,
offering
insights
future
strategies.
Язык: Английский
Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy
Annals of Surgical Oncology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 27, 2024
Язык: Английский
Cancer-associated fibroblasts derived-exosomal circ_0076535 promotes esophageal squamous cell carcinoma progression
Ningning Kang,
Wei Ge,
Jinxiu Hu
и другие.
Technology and Health Care,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Background
Esophageal
cancer
(EC)
is
a
common
malignant
tumor
of
the
digestive
tract
and
an
important
health-related
problem
in
many
developing
countries.
squamous
cell
carcinoma
(ESCC)
most
subtype
EC.
The
cancer-associated
fibroblasts
(CAFs)
are
major
stromal
cells
ESCC
microenvironment.
They
play
role
proliferation,
metastasis,
angiogenesis
chemotherapy
resistance
through
paracrine
processes.
However,
roles
circRNAs
enriched
CAF-derived
exosmes
have
not
been
reported.
Objective
To
explore
mechanisms
how
CAF
affects
proliferation
metastasis
processes
to
investigate
exosomes.
Methods
Exosomes
were
isolated
from
conditional
medium
using
differential
ultracentrifugation,
then
validated
by
Nanosight
analysis.
Exosome
secretion
inhibitor-GW4869
validates
pro-carcinogenic
qRT-PCR
showed
highest
expression
circ_0076535
exosomal
CircRNA,
knockdown
it
confirmed
its
function.
Online
bioinformatics
tool
was
utilized
predict
potential
target
gene
circ_0076535,
captured
miR-145-5p
as
with
high
predictive
value.
targeting
association
between
further
dual
luciferase
reporter
experiment.
stimulation
tumour
development
EMT
exosome
vivo.
Results
In
our
research,
we
found
that
exosomes
increased
migration,
invasion
cells.
Circ_0076535
highly
CAF-exosomes
transferred
into
directly
depend
on
internalization
CAF-exosomal
level
induced
EMT.
Mechanistic
experiments
revealed
acted
sponge
absorb
activated
NF-κB
signaling
pathway.
Conclusions
Conclusively,
promoted
progression
via
miR-145-5p/NF-κB
axis
expected
be
biomarker
for
early
diagnosis
treatment
ESCC.
Язык: Английский